Maria Domenica Cappellini, MD, of the University of Milan, Milan, Italy, discusses the results of the Phase III BELIEVE trial (NCT02604433), which is investigating luspatercept vs. a placebo in adults with β-thalassemia who require regular transfusions. She highlights how luspatercept significantly reduced transfusion burden and was generally well-tolerated. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

свернуть